Skip to main content
SpringerLink
Log in

Uptake and distribution of doxorubicin in hormone-manipulated human breast cancer cells in vitro

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Background: Kinetic resistance to cytotoxic drugs may account for the moderate responsiveness of breast cancer to chemotherapy. In the present study the in vitro effects of estradiol-mediated DNA stimulation on the cellular uptake of the DNA intercalating drug doxorubicin (DOX) were examined in MCF-7 human breast cancer cells. Methods: Using the fluorescent properties of the drug, the cellular uptake was investigated by high performance liquid chromatography (HPLC), and by flow cytometry. Results: The uptake of DOX (0.01–2 μg/ml) by MCF-7 cells in suspension, incubated for 1 and 6 h, showed a strong correlation between the incubation concentration of DOX and the cellular uptake of the drug as measured by HPLC and flow cytometry. Simultaneous exposure of MCF-7 cells, in monolayer culture, to DOX (0.04–0.2 μg/ml) and estradiol (1 nM) for 1–24 h showed no significant difference in uptake of the drug compared to control cultures exposed to DOX in the absence of estradiol. Neither was there a significant difference in uptake of DOX when MCF-7 cells were pretreated with estradiol (1 nM) for 16–24 h followed by a 0.5, 1, 6, and 21/23 h incubation with DOX (0.01–2 μg/ml). Pretreatment with estradiol did not affect the retention of DOX as measured 24 h after a 0.5 h incubation with DOX (2 μg/ml). Furthermore, fluorescence microscopy revealed no difference in the cellular DOX distribution pattern of estradiol-stimulated MCF-7 cultures compared to unstimulated cultures. Conclusion: From this study we can conclude that, for the human MCF-7 breast cancer cells in vitro, the uptake, retention, and cellular distribution of DOX are not influenced by estrogenic manipulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Launchbury AP, Habboubi N: Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 19: 197–228, 1993

    Google Scholar 

  2. The French Epirubicin Study Group: A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol 6: 679–688, 1988

    Google Scholar 

  3. Italian Multicenter Breast Study with Epirubicin: Phase III randomized study of fluorouracil, cpirubicin, and cyclophosphamide vs fluorouracil, doxorubicin, and cyclophos phamide in advanced breast cancer: An Italian multicenter trial. J Clin Oncol 6: 976–982, 1988

    Google Scholar 

  4. Levine M, Bramwell V, Pritchard K, Shepherd L: CEF versus CMF in premenopausal women — Recent update. Sixth International Conference on Adjuvant Therapy of Primary Breast Cancer, St Gallen, Switzerland, February 25–28, 1998, abstract S35

  5. Liu LF, Rowe TC, Yang L, Tewey KM, Chen GL: Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem 258: 15365–15370, 1983

    Google Scholar 

  6. Sinha BK, Katki AG, Bastist G, Cowan KH, Myers CE: Differential formation of hydroxyl radicals by adriamycin in sensitive and resistant MCF-7 human breast cells: implication for the mechanisms of action. Biochemistry 26: 3776–3781, 1987

    Google Scholar 

  7. Chabner BA, Myers CE: Antitumor antibiotics. In: DeVita V, Hellman S, Rosenberg S (eds) Cancer, Principles and Practice of Oncology, 4th edition. JB Lippincott, Philadelphia, 1993, pp 376–380

    Google Scholar 

  8. Beck WT: The cell biology of multiple drug resistance. Biochem Pharmacol 36: 2879–2887, 1987

    Google Scholar 

  9. Endicott JA, Ling V: The biochemistry of P-glycoprotein mediated multidrug resistance. Annu Rev Biochem 58: 137–171, 1989

    Google Scholar 

  10. Lehner M: Reversal of multidrug resistance in breast cancer: many more open questions than answers. Ann Oncol 4: 11–13, 1993

    Google Scholar 

  11. Bontenbal M, Sieuwerts AM, Klijn JGM, Peters HA, Krijnen HLJM, Sonneveld P, Fockens JA: Effect of hormonal manipulation and doxorubicin administration on cell kinetics of human breast cancer cells. Br J Cancer 60: 688–692, 1989

    Google Scholar 

  12. Weichselbaum RR, Hellman S, Piro AJ, Nove JJ, Little JB: Proliferation kinetics of a human breast cancer line in vitro following treatment with 17β-estradiol and 1-β-D-arabinofuranosylcytosine. Cancer Res 38: 2339–2342, 1978

    Google Scholar 

  13. Clarke R, van der Berg HW, Kennedy DJ, Murphy RF: Estrogen receptor status and the response of human breast cancer cell lines to a combination of methotrexate and 17β-estradiol. Br J Cancer 51: 365–369, 1985

    Google Scholar 

  14. Hug V, Johnston D, Finders M, Hortobagyi G: Use of growth stimulatory hormones to improve the in vitro therapeutic index of doxorubicin for human breast tumors. Cancer Res 46: 147–152, 1986

    Google Scholar 

  15. Bontenbal M, Sieuwerts AM, Peters HA, Sonneveld P, Foekens JA, Klijn JGM: Manipulation of cell cycle kinetics: influence on the cytotoxicity of doxorubicin in human breast cancer cells. J Steroid Biochem Molec Biol 37: 1097–1101, 1990

    Google Scholar 

  16. Remvikos Y, Jouve M, Beuzeboc P, Viehl P, Magdelenat H, Pouillart P: Cell cycle modifications of breast cancers during neo-adjuvant chemotherapy: a flow cytometry study on fine needle aspirates. Eur J Cancer 13: 1843–1848, 1993

    Google Scholar 

  17. Daidone MG, Silvestrini R, Valentinis B, Ferrari L, Bartoli C: Changes in cell kinetics induced by primary chemotherapy in breast cancer. Int J Cancer 47: 380–383, 1991

    Google Scholar 

  18. Israel M, Pegg WJ, Wilkinson PM, Garnick M: Liquid chromatographic analysis of adriamycin and metabolites in biological fluids. J Liquid Chromatography 6: 795–809, 1985

    Google Scholar 

  19. Kokenberg E, Sonneveld P, Delwel R, Sizoo W, Hagenbeek A, Löwenberg B: In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry. Leukemia 2: 511–517, 1988

    Google Scholar 

  20. Citro G, Cucco C, Verdina A, Zupi G: Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line. Br J Cancer 64: 534–536, 1991

    Google Scholar 

  21. Taylor CW, Dalton WS, Parrish PR, Gleason MC, Bellamy WT, Thompson FH, Roe DJ, Trent JM: Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br J Cancer 63: 923–929, 1991

    Google Scholar 

  22. Schuurhuis GJ, Broxterman HJ, Cervantes A, van Heijningen ThHM, de Lange JHM, Baak JPA, Pinedo HM, Lankelma J: Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells. J Natl Cancer Inst 81: 1887–1892, 1989

    Google Scholar 

  23. Tokita N, Raju MR: Cell cycle dependent adriamycin uptake in Chinese hamster cells. Eur J Cancer Clin Oncol 21: 243–246, 1985

    Google Scholar 

  24. Minderman H, Linssen P, Wessels J, Haanen C: Cell cycle related uptake, retention and toxicity of idarubicin, daunorubicin and doxorubicin. Anticancer Res 13: 1161–1166, 1993

    Google Scholar 

  25. Ling Y, El-Naggar AK, Priebe W, Perez-Soler R: Cell cycle-dependent cytotoxicity, G2M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol 49: 832–841, 1996

    Google Scholar 

  26. Epstein RJ, Smith PJ, Watson JV, Bleehan NM: Characterisation of VP-16-induced DNA cleavage in oestrogen stimulated human breast cancer cells. Br J Cancer 57: 445–450, 1988

    Google Scholar 

  27. Epstein RJ, Smith PJ: Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with toposiomerase II-interactive antitumor drugs. Cancer Res 48: 297–303, 1988

    Google Scholar 

  28. Epstein RJ, Smith PJ, Watson JV, Waters C, Bleehan NM: Oestrogen potentiates topoisomerase-II-mediated cytotoxicity in an activated subpopulation of human breast cancer cells: Implications for cytotoxic drug resistance in solid tumours. Int J Cancer 44: 501–505, 1989

    Google Scholar 

  29. Shaikh NA, Owen AM, Ghilchik MW, Braunsberg H: Actions of medroxyprogesterone acetate on the efficacy of cytotoxic drugs: Studies with human breast cancer cells in culture. Int J Cancer 43: 458–463, 1989

    Google Scholar 

  30. Shaikh NA, Owen AM, Ghilchik MW, Braunsberg H: Adriamycin action on human breast cancer cells: Enhancement by medroxyprogesterone acetate. Int J Cancer 43: 733–736, 1989

    Google Scholar 

  31. Reed MJ, Ross MS, Ghilchik MW: The effect of oestrogens and medroxyprogesterone acetate on the uptake of cytotoxic drugs by MCF-7 breast cancer cells. Anticancer Res 12: 533–536, 1992

    Google Scholar 

  32. Osborne CK, Kitten L, Arteaga CL: Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol 7: 710–717, 1989

    Google Scholar 

  33. Jancis EM, Carbone R, Loechner KJ, Dannies PS: Estradiol induction of rhodamine 123 efflux and the multidrug resistance pump in rat pituitary tumor cells. Mol Pharmacol 43: 51–56, 1992

    Google Scholar 

  34. Bontenbal M, Sonneveld P, Fockens JA, Klijn JGM: Oestradiol enhances doxorubicin uptake and cytotoxicity in human breast cancer cells (MCF-7). Eur J Cancer Clin Oncol 24: 1409–1414, 1988

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrine Oncology (Department of Medical Oncology), Rotterdam Cancer Institute (Dr. Daniel den Hoed Kliniek) and, University Hospital, Rotterdam, The Netherlands

    Marijke Bontenbal, Anieta M. Sieuwerts, Harry A. Peters, John A. Foekens & Jan G.M. Klijn

  2. Department of Statistics, Rotterdam Cancer Institute (Dr. Daniel den Hoed Kliniek) and, University Hospital, Rotterdam, The Netherlands

    Wim L.J. van Putten

Authors
  1. Marijke Bontenbal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anieta M. Sieuwerts
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Harry A. Peters
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wim L.J. van Putten
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John A. Foekens
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jan G.M. Klijn
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bontenbal, M., Sieuwerts, A.M., Peters, H.A. et al. Uptake and distribution of doxorubicin in hormone-manipulated human breast cancer cells in vitro. Breast Cancer Res Treat 51, 139–148 (1998). https://doi.org/10.1023/A:1006026015448

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006026015448

Search

Navigation